Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

55.83USD
15 Dec 2017
Change (% chg)

$1.88 (+3.48%)
Prev Close
$53.95
Open
$54.00
Day's High
$55.85
Day's Low
$54.00
Volume
252,573
Avg. Vol
79,708
52-wk High
$55.85
52-wk Low
$25.92

Latest Key Developments (Source: Significant Developments)

Enanta Pharma Q4 earnings per share $1.86
Monday, 20 Nov 2017 04:01pm EST 

Nov 20 (Reuters) - Enanta Pharmaceuticals Inc ::Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017.Q4 earnings per share $1.86.Q4 revenue $75.9 million versus I/B/E/S view $73.1 million.Q4 earnings per share view $2.13 -- Thomson Reuters I/B/E/S.  Full Article

Enanta Pharmaceuticals announces new data presentations on EDP-305
Wednesday, 27 Sep 2017 04:14pm EDT 

Sept 27 (Reuters) - Enanta Pharmaceuticals Inc :Enanta Pharmaceuticals announces new data presentations on EDP-305, an FXR agonist for NASH and PBC, at The Liver Meeting 2017.Co has submitted an abstract to AASLD for consideration of late breaking data from its phase 1 clinical study of EDP-305​.  Full Article

Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c
Wednesday, 27 Sep 2017 06:30am EDT 

Sept 27 (Reuters) - Enanta Pharmaceuticals Inc :Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c.Enanta Pharmaceuticals - co expects to receive $15 million milestone payment from Abbvie in quarter ending Dec 31, 2017, upon price reimbursement approval of Maviret in Japan​.Enanta Pharma - expects to get $15 million milestone payment from Abbvie in quarter ending Dec 31, 2017, upon Japan​ price reimbursement approval of Maviret.Enanta Pharmaceuticals -‍in Japan, Maviret is also approved as 12-week option for patients infected with GT3-6, patients with specific challenges​.  Full Article

Enanta pharmaceuticals Q3 loss per share $0.44
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Enanta Pharmaceuticals Inc :Enanta pharmaceuticals reports financial results for its fiscal third quarter ended june 30, 2017.Q3 loss per share $0.44.Q3 revenue $7.5 million versus i/b/e/s view $8.1 million.Q3 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

EC grants Abbvie's Maviret marketing authorization for treatment of Chronic Hepatitis C
Friday, 28 Jul 2017 10:57am EDT 

July 28 (Reuters) - Abbvie Inc ::European Commission grants Abbvie's Maviret (glecaprevir/pibrentasvir) marketing authorization for the treatment of Chronic Hepatitis C in all major genotypes (GT1-6).‍Approval of Maviret is supported by data from eight registrational studies in Abbvie's clinical development program​.  Full Article

Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET
Friday, 23 Jun 2017 07:44am EDT 

June 23 (Reuters) - Enanta Pharmaceuticals Inc :Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6).Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6).Says ‍final european commission decision expected q3 2017​.  Full Article

Enanta Pharmaceuticals reports Q2 loss per share $0.28
Monday, 8 May 2017 04:01pm EDT 

May 8 (Reuters) - Enanta Pharmaceuticals Inc :Enanta Pharmaceuticals reports financial results for its fiscal second quarter ended March 31, 2017.Q2 loss per share $0.28.Q2 revenue $9.0 million versus I/B/E/S view $9.2 million.Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir
Tuesday, 14 Mar 2017 08:00am EDT 

Abbvie Inc : Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c .Priority review follows EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively.  Full Article

Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B
Monday, 27 Feb 2017 06:00am EST 

Enanta Pharmaceuticals Inc : Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie's Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c . Says Abbvie's EMA label expansion is supported by 98 percent svr 12 rate in patients in dedicated phase 3b garnet study .Says chmp positive opinion is supported by data from dedicated phase 3b garnet study.  Full Article

Enanta Pharmaceuticals Q1 loss per share $0.26
Wednesday, 8 Feb 2017 04:02pm EST 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals reports financial results for its fiscal first quarter ended december 31, 2016 . Q1 loss per share $0.26 . Q1 revenue $10.4 million versus I/B/E/S view $11.9 million . Q1 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S . Enanta Pharmaceuticals Inc - expect to complete phase 1 study of edp-305 mid-year and later this year plan to initiate a phase 2 study of edp-305 in pbc . Enanta -expect to complete phase 1 study of edp-305 mid-year and later this year plan to initiate a phase 2 study of edp-305 in pbc .Enanta Pharmaceuticals Inc says also plan initiation of clinical development of our lead rsv compound, edp-938 in calendar 2017.  Full Article

BRIEF-Enanta Pharma Says Abbvie’s Maviret ‍is Now Commercially Available In Japan​

* ENANTA PHARMACEUTICALS - ABBVIE'S MAVIRET HAS BEEN APPROVED FOR REIMBURSEMENT BY MINISTRY OF HEALTH, LABOUR AND WELFARE